CymaBay Therapeutics Inc (NASDAQ:CBAY) – Investment analysts at Oppenheimer issued their FY2017 earnings estimates for CymaBay Therapeutics in a report issued on Monday. Oppenheimer analyst J. Olson expects that the biopharmaceutical company will earn ($0.62) per share for the year. Oppenheimer currently has a “Buy” rating and a $18.00 price target on the stock. Oppenheimer also issued estimates for CymaBay Therapeutics’ Q4 2017 earnings at $0.03 EPS, Q1 2018 earnings at ($0.18) EPS, Q2 2018 earnings at ($0.20) EPS, Q3 2018 earnings at ($0.20) EPS, Q4 2018 earnings at ($0.21) EPS, FY2018 earnings at ($0.79) EPS, FY2019 earnings at ($0.18) EPS, FY2020 earnings at ($0.18) EPS, FY2021 earnings at $0.35 EPS and FY2022 earnings at $0.50 EPS.
CBAY has been the topic of a number of other research reports. BidaskClub raised CymaBay Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 21st. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of CymaBay Therapeutics in a report on Tuesday, November 28th. Zacks Investment Research lowered CymaBay Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 16th. Evercore ISI started coverage on CymaBay Therapeutics in a report on Tuesday, February 13th. They set an “outperform” rating on the stock. Finally, Roth Capital reissued a “buy” rating and set a $27.00 price objective on shares of CymaBay Therapeutics in a report on Thursday, January 25th. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $16.89.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CBAY. Schwab Charles Investment Management Inc. acquired a new stake in CymaBay Therapeutics in the 4th quarter valued at approximately $115,000. Goldman Sachs Group Inc. acquired a new stake in CymaBay Therapeutics in the 4th quarter valued at approximately $197,000. Virtu Financial LLC grew its holdings in CymaBay Therapeutics by 56.2% in the 4th quarter. Virtu Financial LLC now owns 24,735 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 8,899 shares during the last quarter. Sigma Planning Corp grew its holdings in CymaBay Therapeutics by 82.0% in the 4th quarter. Sigma Planning Corp now owns 27,300 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 12,300 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in CymaBay Therapeutics by 7,729.2% in the 4th quarter. Wells Fargo & Company MN now owns 39,146 shares of the biopharmaceutical company’s stock valued at $360,000 after buying an additional 38,646 shares during the last quarter. 61.36% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director Kurt Von Emster sold 4,300 shares of the stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $10.21, for a total transaction of $43,903.00. Following the transaction, the director now owns 90,000 shares of the company’s stock, valued at approximately $918,900. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 978,140 shares of company stock worth $11,761,941. 15.10% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/03/14/cymabay-therapeutics-inc-cbay-forecasted-to-post-fy2017-earnings-of-0-62-per-share.html.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.